enVVeno Medical Corporation (NVNO)

NASDAQ: NVNO · IEX Real-Time Price · USD
5.28
-0.18 (-3.30%)
At close: Mar 27, 2024, 4:00 PM
5.44
+0.16 (3.03%)
After-hours: Mar 27, 2024, 4:55 PM EDT

Company Description

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.

The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease.

Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg.

The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.

enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

enVVeno Medical Corporation
enVVeno Medical logo
Country United States
Founded 1987
Industry Medical Devices
Sector Healthcare
Employees 31
CEO Robert A. Berman

Contact Details

Address:
70 Doppler
Irvine, California 92618
United States
Phone 949-261-2900
Website envveno.com

Stock Details

Ticker Symbol NVNO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661053
CUSIP Number 29415J106
ISIN Number US29415J1060
Employer ID 33-0936180
SIC Code 3841

Key Executives

Name Position
Robert A. Berman Chief Executive Officer and Director
Craig Thomas Glynn Chief Financial Officer, Treasurer and Secretary
Dr. Hamed Alavi Ph.D. Senior Vice President and Chief Technology Officer
Dr. Marc H. Glickman M.D. Senior Vice President and Chief Medical Officer
Warren Hancock Co-founder
Dr. Benedict Broennimann M.D. Chief Medical Officer of Outside of United States

Latest SEC Filings

Date Type Title
Mar 6, 2024 8-K Current Report
Feb 29, 2024 10-K Annual Report
Feb 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 7, 2023 8-K Current Report
Nov 16, 2023 8-K Current Report
Nov 3, 2023 EFFECT Notice of Effectiveness
Nov 3, 2023 DEF 14A Other definitive proxy statements
Oct 26, 2023 S-3 Registration statement under Securities Act of 1933